Researchers sought to analyze the occurrence and severity of cytokine release syndrome in patients with relapsed/refractory multiple myeloma who recieve CAR-T therapy.
Prospective sequencing of samples provided new genetic information for 24.8 percent of patients, which changed risk category for 16.2 percent.
A single-arm, phase 2 trial was conducted to assess response to treatment with carfilzomib plus cyclophosphamide and dexamethasone among patients with relapsed/refractory multiple myeloma.
Researchers sought to determine whether CAR-T therapy would be an effective treatment for patients with relapsed/refractory multiple myeloma.
Semistructured interviews of patients and clinicians were conducted to explore how this disease affects the day-to-day lives of patients.
Ways to improve representation of African Americans in clinical trials could be extrapolated to other underrepresented groups.
The approval is supported by data from the multicenter, randomized, open-label phase 3 IKEMA trial.
Progression-free, three-year overall survival similar for lenalidomide maintenance regimen without dexamethasone.
Researchers sought to determine whether adding daratumumab to standard care for patients with multiple myeloma was a cost-effective option.
Researchers sought to determine whether adding ixazomib to treatment with lenalidomide plus dexamethasone would give a benefit to patients with newly diagnosed multiple myeloma.
